Navigation Links
Ukrainian President Yushchenko: Pharmaceuticals 'Very Important'
Date:9/30/2008

- MaxWell Biocorporation Wins Presidential Support for Faster Registration

of Modern Medicines in Ukraine -

WASHINGTON, Sept. 30 /PRNewswire/ -- Dr. Kenneth Alibek, President and CEO of MaxWell Biocorporation, LLC, and Dr. Peter M. Leitner, President of MaxWell USA, LLC, participated today in a presidential breakfast to honor Ukrainian President Victor Yushchenko.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080624/NETU078LOGO )

The breakfast was hosted by the U.S.-Ukraine Business Council (USUBC). Nearly 100 senior business leaders, academics, and diplomats attended this invitation-only event, including three former United States ambassadors to Ukraine and the current US Ambassador to Kyiv William Taylor.

President Yushchenko discussed the current political and economic situation in Ukraine. The President repeated his strong support for Ukraine's further integration into the Euro-Atlantic community as shown by the recent events in Georgia, spoke about Ukraine's business environment, thanked the U.S. companies for their investments in Ukraine, and urged American investors to participate in even more projects in Ukraine.

Asking the first question, Dr. Alibek asked the Ukrainian President about prospects for ensuring timely registration and licensing procedures for foreign pharmaceutical companies with established production facilities in Ukraine, in order to expedite access to the latest medicines for the people of Ukraine. Companies are experiencing unnecessary and costly delays in this area, Dr. Alibek noted.

President Yushchenko stated that it is very important for Ukraine to have the latest and most effective pharmaceuticals. The Ukrainian President promised he would monitor this situation, and suggested to Dr. Alibek that he work closely with Mr. Yushchenko's staff to resolve this issue.

Later the same day, President Yushchenko met with President Bush at the White House, spoke at the National Press Club, and laid a wreath at the monument to famous Ukrainian poet Taras Shevchenko in Washington, DC.

About MaxWell

MaxWell Biocorporation (http://www.max-well.com) is a U.S.-based, privately-held international medical and pharmaceutical company with wholly owned subsidiaries and affiliates in the United States and Ukraine dedicated to increasing life expectancy and improving the quality of life of people in Ukraine and other underserved emerging healthcare markets in the former Soviet Union. MaxWell targets oncological, cardiological, chronic infectious and autoimmune disorders and diseases through the development, production, and introduction into clinical practice of sophisticated, high quality, and affordable off-patent generic biopharmaceutical and chemopharmaceutical medicines and the latest diagnostic and therapeutic methods. MaxWell = "Maximum Wellness."

"We Help You Live Longer"

Contact:

Alex Meerovich

A.Meerovich@max-well.com

202-454-3403 Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Kenneth Alibek https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=78826 Peter Leitner https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=78827


'/>"/>
SOURCE MaxWell Biocorporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. KGI Names Kerry Howell Vice President for Advancement
2. Vical Names Andrew de Guttadauro Vice President, Corporate Development
3. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
4. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
5. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
6. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
7. CryoLife Names Philip Theodore as Vice President, General Counsel
8. Dr. Keith Wilson Named President and Chief Scientific Officer of Takeda San Diego
9. AGI Dermatics President to be Keynote Speaker at the 11th Annual Sunscreen Symposium
10. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
11. Premier Research Appoints Melissa Jones as Vice President, International Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
(Date:6/23/2016)... ... , ... STACS DNA Inc., the sample tracking software company, today announced that ... joined STACS DNA as a Field Application Specialist. , “I am thrilled that ... of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
Breaking Biology Technology:
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
Breaking Biology News(10 mins):